CLINICAL EVALUATION OF A NEW FORMULATION OF 99mTc-TRODAT-1 FOR SPECT IMAGING IN PARKINSON PATIENTS AND VOLUNTEER SUBJECTSAbstract
This study was conducted to evaluate the clinical usefulness of new developed kit of 99mTc-TRODAT-1 to differentiate PD(Parkinson disease) from volunteer subjects. The 925-1111MBq (25-30 mCi) 99mTc-TRODAT-1 samples were reconstituted by boiling water bath method. Fourteen subjects (women = 6, men = 8, age range 24 – 72, mean = 54.4) have been participated in this approach. The control group included (women = 2, men = 2, age = 25-70, mean = 54.75) and the other group included 10 PD patients (women = 4, men = 6, age = 42-72, mean = 54.1) the different stages of PD. Hoehin and Yahr Scale criteria was chosen for clinical evaluation of PD patients. Brain SPECT study has been performed using a single-headed gamma camera 3 hours post intravenous injection. Visual inspection of radiotracer uptake in the striatum and semi-quantitative analyses were performed. The radio-HPLC analysis indicated that the 99mTc-TRODAT-1 samples were successfully prepared with a radiochemical purity over 90 %. Semi-quantitative analysis demonstrated that the negative relation between the striatal uptake and disease severity has been observed. The sensitivity and specificity of 99mTc-TRODAT-1 brain imaging to detect PD were 100 % in our investigation. The SPECT brain imaging with a new developed kits of 99mTc-TRODAT-1can be recommended as a useful modality for diagnosis and evaluation of the severity of PD in clinical practice.
S. M. Saadati, A. Kiasat, M. Mousavinia, F. Ahmadi, R. Ahadi, S. Rafie, B. Etesami, M. Erfani and A. Doroudi *
School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
15 November, 2017
31 January, 2018
06 February, 2018
01 August, 2018